<DOC>
	<DOCNO>NCT02106546</DOCNO>
	<brief_summary>This 2 arm Phase 3 study evaluate safety efficacy addition veliparib plus carboplatin paclitaxel versus addition placebo plus carboplatin paclitaxel subject advance metastatic squamous NSCLC .</brief_summary>
	<brief_title>Randomized , Double-Blind , Multicenter , Study Comparing Veliparib Plus Carboplatin Paclitaxel Versus Placebo Plus Carboplatin Paclitaxel Previously Untreated Advanced Metastatic Squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Life expectancy &gt; 12 week 2 . Subject must cytologically histologically confirm squamous NSCLC . 3 . Subject must advance metastatic squamous NSCLC amenable surgical resection radiation curative intent time study Screening . 4 . Subjects recurrent squamous NSCLC surgical treatment amenable surgical resection radiation curative intent eligible . 5 . Subject must least 1 unidimensional measurable NSCLC lesion Computerized Tomography ( CT ) scan define Response Evaluation Criteria In Solid Tumors ( RECIST version 1.1 ) . 1 . Subject know hypersensitivity paclitaxel drug formulate polyethoxylated castor oil ( Cremophor ) . 2 . Subject know hypersensitivity platinum compound . 3 . Subject peripheral neuropathy &gt; = grade 2 . 4 . Subject nonsquamous NSCLC , know Epidermal Growth Factor Receptor ( EGFR ) mutation exon 19 deletion L858R mutation exon 21 , know Anaplastic Lymphoma Kinase ( ALK ) gene rearrangement . 5 . Subject receive prior cytotoxic chemotherapy ( include definitive chemoradiotherapy ) NSCLC , except adjuvant neoadjuvant therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>carboplatin</keyword>
	<keyword>Randomized</keyword>
	<keyword>veliparib</keyword>
	<keyword>Advanced</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Overall Survival</keyword>
	<keyword>Squamous</keyword>
	<keyword>placebo control</keyword>
	<keyword>ABT-888</keyword>
	<keyword>Poly Adenosine diphosphate ( ADP ) -ribose Polymerase ( PARP )</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>paclitaxel</keyword>
</DOC>